The emerging treatment landscape of nonalcoholic steatohepatitis has “exploded” as understanding of the pathogenesis grows, according to a presenter at GUILD 2022.
“We [have] a huge armamentarium of drugs in development,” Manal F. Abdelmalek, MD, MPH, professor of medicine and director of the NAFLD Clinical Research Program at Duke University School of Medicine, told attendees. “In my opinion, the future of NASH is going to be binding combination therapies, for which we have a foundation of anti-metabolic therapy, coupled with anti-inflammatory or anti-fibrotic therapy, depending on where patients are in the disease spectrum.”